• $3.1M
    Market Cap
  • -87.49%
    1-Year Change
  • Drug Manufacturers - Specialty & Generic
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
100,000
+89.20%
52,855
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
142,000
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
+100.00%
-42,000
-179.46%
52,855
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
742,002
N/A
Research and Development Expense
-4.1M
+12.05%
-3.6M
+2.89%
-3.5M
+136.28%
-1.5M
N/A
Depreciation and Amortization Expense
290,107
+5,210.40%
5,463
-19.79%
6,811
+14.05%
5,972
N/A
Total Operating Expenses
11.9M
+54.84%
7.7M
+30.61%
5.9M
+130.69%
2.6M
N/A
Operating Profit
-11.9M
+54.84%
-7.7M
+30.61%
-5.9M
+130.69%
-2.6M
N/A
Interest Income
1,090
-97.14%
38,138
-51.80%
79,117
N/A
N/A
N/A
Interest Expense
-8,730
+0.44%
-8,692
-99.65%
-2.5M
+171.39%
-917,879
N/A
Interest Income and Expense and Net
-7,640
-125.95%
29,446
+101.22%
-2.4M
+162.77%
-917,879
N/A
Total Nonoperating Income and Expense
195,155
+113.47%
-1.4M
+106.85%
-700,341
+47.70%
-474,170
N/A
Income before Taxes
-11.9M
+54.84%
-7.7M
+16.74%
-6.6M
+117.69%
-3.0M
N/A
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
109,235
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
N/A
N/A
-9.1M
+38.71%
-6.6M
+117.69%
-3.0M
N/A
Net Income from Continuing Operations Applicable to Common
N/A
N/A
-9.1M
+38.71%
-6.6M
+112.71%
-3.1M
N/A
Basic EPS and Net Income
-7.16
+124.45%
-3.19
-9.63%
-3.53
+1,117.24%
-0.29
N/A
Diluted EPS and Net Income
-7.16
+116.97%
-3.30
-6.52%
-3.53
+1,117.24%
-0.29
N/A
Basic Weighted Average Shares
1.6M
-42.93%
2.9M
+53.79%
1.9M
-81.97%
10.4M
N/A
Diluted Weighted Average Shares
1.6M
-43.27%
2.9M
+54.71%
1.9M
-81.97%
10.4M
N/A
Balance Sheet
Cash and Cash Equivalents
334,005
-82.61%
1.9M
-25.47%
2.6M
-69.39%
8.4M
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
2.9M
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
334,005
-82.61%
1.9M
-64.86%
5.5M
-35.09%
8.4M
N/A
Total Current Assets
502,911
-77.25%
2.2M
-60.47%
5.6M
-34.80%
8.6M
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
121,685
+5.93%
114,874
N/A
Property and Plant and Equipment and Net
17,319
-10.56%
19,364
-22.00%
24,827
+97.16%
12,592
N/A
Total Long-Term Assets
29,441
+52.04%
19,364
-22.00%
24,827
+283.13%
6,480
N/A
Total Assets
10.5M
+317.99%
2.5M
-57.89%
6.0M
-31.22%
8.7M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
1.4M
+1.14%
1.4M
+90.16%
731,088
+6.65%
685,473
N/A
Total Current Liabilities
8.0M
+419.43%
1.5M
+47.16%
1.0M
+6.82%
975,676
N/A
Total Long-Term Debt
600,000
-94.00%
10.0M
+7,302.53%
135,089
-97.00%
4.5M
N/A
Total Long-Term Liabilities
254,640
-3.31%
263,369
-63.35%
718,639
+1,043.91%
62,823
N/A
Total Liabilities
8.2M
+357.48%
1.8M
-5.21%
1.9M
+94.32%
975,676
N/A
Retained Earnings
-46.3M
+33.90%
-34.6M
+35.96%
-25.4M
+185.93%
-8.9M
N/A
Total Stockholders Equity
2.3M
+217.91%
709,152
-82.51%
4.1M
-47.18%
7.7M
N/A
Total Shares Outstanding
2.0M
-50.36%
4.1M
+102.95%
2.0M
-85.23%
13.6M
N/A
Cash Flow
Cash from Operating Activities
-9.5M
+29.40%
-7.3M
+31.29%
-5.6M
+105.91%
-2.7M
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
19,046
N/A
N/A
N/A
Cash from Investing Activities
-3.1M
-204.83%
2.9M
+203.04%
-2.8M
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
11.0M
+191.66%
3.8M
+46.11%
2.6M
-75.81%
10.6M
N/A
Financials Ratio
Gross Margin
N/A
N/A
-42.00%
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
-7,696.17%
-30.96%
-11,148.20%
N/A
N/A
N/A
Return on Assets
N/A
N/A
-216.24%
+139.52%
-90.28%
N/A
N/A
N/A
Return on Equity
N/A
N/A
-383.84%
+241.58%
-112.37%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
89.20%
N/A
N/A
N/A
N/A
N/A
Current Ratio
0.06
-95.62%
1.44
-73.14%
5.37
N/A
N/A
N/A
Cash Ratio
0.04
-96.65%
1.25
-49.36%
2.47
N/A
N/A
N/A
Debt-to-Equity Ratio
0.89
-94.46%
16.06
+7,419.57%
0.21
N/A
N/A
N/A
Debt-to-Assets Ratio
0.19
-95.79%
4.54
+3,023.51%
0.15
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow